Drug Development

T-cell lymphoma patients achieve long-lasting responses with human antibody drug

Published in Cancer Weekly, September 28th, 2004

Genmab A/S announced that cutaneous T-cell lymphoma (CTCL) patients in the HuMax-CD4 phase 2 studies achieved long-lasting responses, with an average response duration of more than 6.6 months.

This duration of response data is based on an analysis of responding mycosis fungoides (MF) patients at all dose levels, 280, 560 and 980 mg.

In addition, median time to disease progression of all 38 MF patients in the 2 phase 2 studies is more than 5.7 months. Disease progression is defined as an increase in disease that is more than 25% above the baseline measurement taken when patients entered the study.

The average duration of response...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-09-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry